• Cat-intel
  • MedIntelliX
  • Resources
  • About Us
  • Request Free Sample ×

    Kindly complete the form below to receive a free sample of this Report

    Leading companies partner with us for data-driven Insights

    clients tt-cursor

    Graves Ophthalmopathy Market

    ID: MRFR/HC/38944-HCR
    100 Pages
    Rahul Gotadki
    September 2025

    Graves Ophthalmopathy Market Research Report By Treatment Type (Medical Therapy, Radiotherapy, Surgery), By Disease Severity (Mild, Moderate, Severe), By Patients' Population (Newly Diagnosed, Relapsed/Refractory, Resistant) and By Regional (North America, Europe, South America, Asia Pacific, Middle East and Africa) - Forecast to 2032

    Share:
    Download PDF ×

    We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

    Graves Ophthalmopathy Market Research Report -Forecast to 2035 Infographic
    Purchase Options
    $ 4,950.0
    $ 5,950.0
    $ 7,250.0

    Graves Ophthalmopathy Market Summary

    The Global Graves Ophthalmopathy Market is projected to grow from 1.73 USD Billion in 2024 to 2.86 USD Billion by 2035.

    Key Market Trends & Highlights

    Graves Ophthalmopathy Key Trends and Highlights

    • The market is expected to experience a compound annual growth rate (CAGR) of 4.65 percent from 2025 to 2035.
    • By the end of 2035, the market valuation is anticipated to reach 2.86 USD Billion, reflecting a robust growth trajectory.
    • In 2024, the market is valued at 1.73 USD Billion, indicating a solid foundation for future expansion.
    • Growing adoption of innovative treatment options due to increasing awareness of Graves Ophthalmopathy is a major market driver.

    Market Size & Forecast

    2024 Market Size 1.73 (USD Billion)
    2035 Market Size 2.86 (USD Billion)
    CAGR (2025-2035) 4.65%

    Major Players

    Teva Pharmaceutical Industries Ltd., Novartis AG, Johnson & Johnson, Gilead Sciences, Hoffmann-La Roche, Amgen, Merck & Co, Pfizer, AstraZeneca, Bristol-Myers Squibb, GlaxoSmithKline, Bayer AG, Sanofi, Eli Lilly and Company, AbbVie

    Graves Ophthalmopathy Market Trends

    The Graves Ophthalmopathy Market is supposed to get increasing sales owing to rising occurrence of Graves’ disease. Several key factors can be identified as active drivers of market growth, such as the deepening of patients’ knowledge about the disease, improvement of diagnostic methods, and better availability of specialized health services. In particular, novel concepts of immunotherapy and gene therapy offer new possibilities. Newest trends include increasing attention to the development of patient-centered, personalized medicines. In addition, there is an increase in telemedicine services for providing follow-up and care, especially in low-access areas.

    The increasing prevalence of autoimmune disorders, coupled with heightened awareness and advancements in diagnostic techniques, appears to be driving growth in the Graves Ophthalmopathy market.

    National Institutes of Health (NIH)

    Graves Ophthalmopathy Market Drivers

    Market Growth Projections

    Growing Geriatric Population

    The aging global population is a notable driver for the Global Graves Ophthalmopathy Market Industry. As individuals age, the likelihood of developing thyroid-related disorders, including Graves disease, increases. Current demographic trends indicate that by 2030, the number of people aged 60 and above will surpass 1.4 billion worldwide. This demographic shift is likely to lead to a corresponding rise in cases of Graves ophthalmopathy, necessitating increased healthcare resources and treatment options. Consequently, the market is poised for growth, with projections suggesting a significant rise in demand for therapies and interventions tailored to this age group.

    Increased Awareness and Diagnosis

    Heightened awareness regarding Graves ophthalmopathy and its symptoms is fostering earlier diagnosis and intervention, thereby propelling the Global Graves Ophthalmopathy Market Industry. Educational campaigns and initiatives by healthcare organizations have led to improved recognition of the condition among both healthcare professionals and the general public. This increased awareness is crucial, as timely diagnosis can significantly impact treatment efficacy and patient quality of life. As a result, the market is expected to experience a compound annual growth rate of 4.65% from 2025 to 2035, reflecting the ongoing efforts to enhance understanding and management of this complex disorder.

    Advancements in Treatment Modalities

    Innovations in treatment options for Graves ophthalmopathy are significantly influencing the Global Graves Ophthalmopathy Market Industry. Recent developments in therapies, including monoclonal antibodies and surgical interventions, have improved patient outcomes and reduced the severity of symptoms. For instance, the introduction of teprotumumab, a targeted therapy, has shown promising results in clinical trials, leading to its approval in various regions. These advancements not only enhance patient care but also contribute to the market's growth, with projections indicating an increase to 2.86 USD Billion by 2035, driven by the demand for more effective and personalized treatment approaches.

    Rising Prevalence of Thyroid Disorders

    The increasing incidence of thyroid disorders, particularly Graves disease, is a primary driver for the Global Graves Ophthalmopathy Market Industry. As per recent health statistics, the prevalence of hyperthyroidism is estimated to affect approximately 1.2% of the global population. This rise correlates with an uptick in Graves ophthalmopathy cases, which affects around 25% to 50% of individuals with Graves disease. Consequently, the market is projected to reach 1.73 USD Billion in 2024, reflecting the growing need for effective treatment options and management strategies for patients suffering from this debilitating condition.

    Regulatory Support for Treatment Innovations

    Regulatory bodies are increasingly supporting the development and approval of new therapies for Graves ophthalmopathy, which is positively impacting the Global Graves Ophthalmopathy Market Industry. Initiatives aimed at expediting the review process for innovative treatments, such as the FDA's Breakthrough Therapy designation, are encouraging pharmaceutical companies to invest in research and development. This regulatory environment fosters a landscape conducive to the introduction of novel therapies that address unmet medical needs. As a result, the market is likely to expand, driven by the influx of new treatment options that enhance patient care and outcomes.

    Market Segment Insights

    Graves Ophthalmopathy Market Treatment Type Insights

    The Treatment Type segment of the Graves Ophthalmopathy Market is divided into Medical Therapy, Radiotherapy, and Surgery. Medical Therapy is the leading segment because medications, such as corticosteroids, immunosuppressive drugs, and biologics, used in curbing inflammation and suppressing the immune system are effective. Radiotherapy is another popular treatment. The treatment method utilizes radiation in reducing inflammation and shrinking the enlarged muscle. Finally, Surgery is a method of the last resort. Orbital decompression relieves pressure on the optic nerve by providing more space for the eye.The Graves Ophthalmopathy Market is worth USD 1.89 billion in 2024.

    It is estimated to expand at a CAGR of 4.8% from 2023 to 2032. The major drivers to this growth are the increasing prevalence of Graves’ disease, the ever-increasing health care expenditure and advancements in treatment.

    Source: Primary Research, Secondary Research, Market Research Future Database and Analyst Review

    Graves Ophthalmopathy Market Disease Severity Insights

    The Graves Ophthalmopathy Market is segmented by disease severity into mild, moderate, and severe. The moderate segment is expected to hold the largest market share in 2023, accounting for around 45% of the Graves Ophthalmopathy Market revenue. The severe segment is expected to reach the highest CAGR of 5.2% during the forecast period. The mild segment is characterized by symptoms such as eyelid retraction, proptosis, and mild inflammation. The moderate segment includes patients with more severe symptoms, such as diplopia, corneal exposure, and optic nerve involvement.The severe segment includes patients with the most severe symptoms, such as blindness and disfigurement.

    The market growth for the moderate and severe segments is attributed to the increasing prevalence of Graves' disease, which is the underlying cause of Graves' ophthalmopathy. The rising awareness of the condition and the availability of new treatment options are also contributing to market growth.

    Graves Ophthalmopathy Market Patients' Population Insights

    The Graves Ophthalmopathy Market segmentation by Patients' Population into 'Newly Diagnosed', 'Relapsed/Refractory', and 'Resistant' provides valuable insights into the characteristics and dynamics of each patient group. In 2023, the 'Newly Diagnosed' segment accounted for a significant share of the Graves Ophthalmopathy Market revenue, driven by the increasing incidence of Graves' disease and the need for early diagnosis and treatment.

    This segment is expected to continue to grow steadily in the coming years due to the rising awareness of Graves' disease and the availability of advanced diagnostic techniques.The 'Relapsed/Refractory' segment represents patients who have experienced a relapse or have not responded to initial treatment. This segment is characterized by more severe symptoms and requires specialized treatment approaches. The increasing prevalence of relapsed/refractory Graves Ophthalmopathy is expected to drive the growth of this segment in the coming years. The 'Resistant' segment includes patients who do not respond to conventional treatment options and require aggressive therapies.

    This segment is relatively small but is expected to grow as the understanding of Graves Ophthalmopathy and its treatment modalities improves.

    Get more detailed insights about Graves Ophthalmopathy Market Research Report -Forecast to 2035

    Regional Insights

    The regional segmentation of the Graves Ophthalmopathy market offers insights into the market's geographic distribution and its performance across different regions. North America is expected to hold the largest market share in 2023, with a significant contribution from the United States. Europe is projected to follow North America, driven by the presence of a large patient population and well-established healthcare systems. The Asia Pacific region is anticipated to exhibit the highest growth rate during the forecast period, owing to rising awareness about the condition and increasing healthcare expenditure.

    South America and the Middle East and Africa are expected to account for a smaller share of the market but are projected to grow steadily over the forecast period. Key factors driving regional market growth include the prevalence of Graves' disease, healthcare infrastructure, government initiatives, and the availability of treatment options.

    Graves Ophthalmopathy Market Regional Insights

    Source: Primary Research, Secondary Research, Market Research Future Database and Analyst Review

    Key Players and Competitive Insights

    Major players in Graves Ophthalmopathy Market are constantly striving to gain a competitive edge by investing in research and development, expanding their product portfolio, and forming strategic partnerships. Leading Graves Ophthalmopathy Market players are focusing on developing innovative treatments and therapies to cater to the evolving needs of patients. The Graves Ophthalmopathy Market industry is witnessing the emergence of novel therapeutic approaches, such as gene therapy and cell-based therapies, which hold promise for improving patient outcomes. 

    Furthermore, key players are actively involved in clinical trials and collaborations to evaluate the efficacy and safety of new treatment modalities. The competitive landscape is characterized by a mix of established pharmaceutical companies and emerging biotechnology firms, each bringing their unique strengths and expertise to the market.A leading player in the Graves Ophthalmopathy Market is Teva Pharmaceutical Industries Ltd. The company has a strong presence in the market with a broad portfolio of ophthalmic products, including treatments for Graves ophthalmopathy. Teva is committed to advancing research and development to bring innovative therapies to patients. 

    It has a robust pipeline of potential treatments for Graves ophthalmopathy, including novel formulations and targeted therapies. The company's global reach and established distribution channels provide it with a competitive advantage in the market.A notable competitor in the Graves Ophthalmopathy Market is Novartis AG. The company has a strong focus on ophthalmology and is dedicated to developing and commercializing innovative treatments for eye diseases. Novartis has a portfolio of products for Graves ophthalmopathy, including immunomodulatory therapies and surgical devices.

    The company's research and development efforts are centered on advancing the understanding of Graves ophthalmopathy and developing new treatments to improve patient outcomes. Novartis's global presence and strong brand reputation make it a formidable competitor in the market.

    Key Companies in the Graves Ophthalmopathy Market market include

    Industry Developments

    The Graves Ophthalmopathy Market is poised to reach a valuation of USD 2.5 billion by 2032, exhibiting a CAGR of 4.56% during the forecast period of 2024-2032. The increasing prevalence of Graves' disease, coupled with growing awareness of the condition, is driving market expansion. Recent advancements in treatment modalities, such as the introduction of targeted therapies and surgical techniques, are expected to further fuel market growth. Key players in the market are actively involved in research and development initiatives to enhance treatment outcomes and expand their product portfolios.

    Strategic collaborations and partnerships are also on the rise, aiming to combine expertise and resources to address unmet medical needs.

    Future Outlook

    Graves Ophthalmopathy Market Future Outlook

    The Graves Ophthalmopathy Market is projected to grow at a 4.65% CAGR from 2024 to 2035, driven by advancements in treatment options and increasing awareness.

    New opportunities lie in:

    • Develop targeted therapies utilizing monoclonal antibodies for enhanced efficacy.
    • Expand telemedicine services for remote patient monitoring and consultations.
    • Invest in AI-driven diagnostic tools to improve early detection and treatment planning.

    By 2035, the Graves Ophthalmopathy Market is expected to achieve substantial growth, reflecting evolving treatment paradigms and increased patient engagement.

    Market Segmentation

    Graves Ophthalmopathy Market Regional Outlook

    • North America
    • Europe
    • South America
    • Asia Pacific
    • Middle East and Africa

    Graves Ophthalmopathy Market Treatment Type Outlook

    • Medical Therapy
    • Radiotherapy
    • Surgery

    Graves Ophthalmopathy Market Disease Severity Outlook

    • Mild
    • Moderate
    • Severe

    Graves Ophthalmopathy Market Patients' Population Outlook

    • Newly Diagnosed
    • Relapsed/Refractory
    • Resistant

    Report Scope

    Report Attribute/Metric Details
    Market Size 2022 1.6(USD Billion)
    Market Size 2023 1.67(USD Billion)
    Market Size 2032 2.5(USD Billion)
    Compound Annual Growth Rate (CAGR) 4.56% (2024 - 2032)
    Report Coverage Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
    Base Year 2023
    Market Forecast Period 2024 - 2032
    Historical Data 2019 - 2023
    Market Forecast Units USD Billion
    Key Companies Profiled Johnson Johnson, Gilead Sciences, F. HoffmannLa Roche, Amgen, Teva Pharmaceutical Industries, Merck Co, Pfizer, AstraZeneca, BristolMyers Squibb, Novartis, GlaxoSmithKline, Bayer AG, Sanofi, Eli Lilly and Company, AbbVie
    Segments Covered Treatment Type, Disease Severity, Patients' Population, Regional
    Key Market Opportunities Growing prevalence of thyroid disorders Advancements in diagnosis and treatment Rising awareness about GO Increasing government initiatives Expanding research and development
    Key Market Dynamics Increasing Prevalence Demand for Specialized Drugs Technological Advancements Growing Awareness Government Support
    Countries Covered North America, Europe, APAC, South America, MEA

    FAQs

    What is the market size of the Graves Ophthalmopathy market?

    The Graves Ophthalmopathy market is expected to reach USD 2.5 billion by 2032, growing at a CAGR of 4.56% from 2024 to 2032.

    Which region is expected to dominate the Graves Ophthalmopathy market?

    North America is expected to dominate the Graves Ophthalmopathy market throughout the forecast period.

    What are the key factors driving the growth of the Graves Ophthalmopathy market?

    The rising prevalence of Graves' disease, increasing awareness about Graves Ophthalmopathy, and technological advancements in treatment are key factors driving the growth of the Graves Ophthalmopathy market.

    What are the major applications of Graves Ophthalmopathy treatment?

    The major applications of Graves Ophthalmopathy treatment include medical therapy, orbital decompression surgery, and eyelid surgery.

    Who are the key competitors in the Graves Ophthalmopathy market?

    Major players in the Graves Ophthalmopathy market include Allergan, Santen Pharmaceutical, Novartis, and Pfizer.

    What is the expected CAGR of the Graves Ophthalmopathy market from 2024 to 2032?

    The Graves Ophthalmopathy market is expected to grow at a CAGR of 4.56% from 2024 to 2032.

    Which region is expected to have the highest growth rate in the Graves Ophthalmopathy market?

    Asia Pacific is expected to have the highest growth rate in the Graves Ophthalmopathy market during the forecast period.

    What are the challenges faced by the Graves Ophthalmopathy market?

    Lack of awareness about Graves Ophthalmopathy and limited access to treatment options pose challenges to the growth of the Graves Ophthalmopathy market.

    What are the opportunities for growth in the Graves Ophthalmopathy market?

    Growing demand for minimally invasive treatments and increasing research and development activities present opportunities for growth in the Graves Ophthalmopathy market.

    What are the key trends in the Graves Ophthalmopathy market?

    Rising adoption of personalized medicine, advancements in imaging techniques, and increasing focus on early diagnosis are key trends in the Graves Ophthalmopathy market.

    Report Infographic
    Free Sample Request

    Kindly complete the form below to receive a free sample of this Report

    Customer Strories

    “I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

    Victoria Milne Founder
    Case Study

    Chemicals and Materials